menu search

MGNX / MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, March 15, 2023, at 4:30 pm ET. Read More
Posted: Mar 7 2023, 18:00
Author Name: GlobeNewsWire
Views: 103154

MGNX News  

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

By Zacks Investment Research
August 14, 2023

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered more_horizontal

Why Shares of MacroGenics Are Jumping Thursday

By The Motley Fool
August 10, 2023

Why Shares of MacroGenics Are Jumping Thursday

MacroGenics saw a big jump in net income. It receives royalties from Sanofi for breast cancer drug Tzield. more_horizontal

MacroGenics, Inc. (MGNX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 9, 2023

MacroGenics, Inc. (MGNX) Q2 2023 Earnings Call Transcript

MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jim Karrels - VP and CFO Scott Koenig more_horizontal

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

By GlobeNewsWire
July 31, 2023

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing an more_horizontal

MacroGenics: Non-Dilutive Funding Propels Drug Candidates (Rating Upgrade)

By Seeking Alpha
May 29, 2023

MacroGenics: Non-Dilutive Funding Propels Drug Candidates (Rating Upgrade)

MacroGenics demonstrates promise with its drug lorigerlimab for mCRPC treatment, despite a recent 18% stock price drop. Q1 2023 showed financial growt more_horizontal

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 9, 2023

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $1.07. This compares to loss of $1.08 per more_horizontal

MacroGenics to Participate in Upcoming Investor Conferences

By GlobeNewsWire
April 24, 2023

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializ more_horizontal

Why MacroGenics Stock Inched Higher on Monday

By The Motley Fool
March 20, 2023

Why MacroGenics Stock Inched Higher on Monday

Two analysts raised their price targets on the cancer-focused biotech. They are the latest prognosticators to adjust their takes on the company follow more_horizontal


Search within

Pages Search Results: